MiMedx Group, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joseph H. Capper
- Full Time Employees
- 808
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1775 West Oak Commons Court, NE Marietta GA United States of America 30062
- IPO Date
- Feb 12, 2008
- CIK
- 0001376339
- Website
- mimedx.com
- Similar Companies
- Business
- MiMedx Group, Inc. is a biopharmaceutical enterprise dedicated to developing and commercializing regenerative biomaterial products and bioimplants derived from human placental tissues. The company employs its patented and proprietary PURION process to prepare these allografts, ensuring the retention of the tissue’s inherent biological properties, including crucial regulatory proteins. This distinctive processing method incorporates aseptic techniques alongside terminal sterilization to deliver robust solutions. Its portfolio encompasses a variety of advanced tissue-based products. EpiFix, a flagship offering, is a dehydrated human amnion/chorion membrane allograft designed as a protective barrier for persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. AmnioFix, also a dehydrated human amnion/chorion membrane allograft, serves in surgical recovery, including applications in orthopedics, spine, and sports medicine. A micronized injectable form of AmnioFix, known as mdHACM, is currently under clinical investigation for conditions like knee osteoarthritis, having received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. EpiCord, a dehydrated human umbilical cord allograft, leverages hyaluronic acid and collagen to foster a healing environment in advanced wound care and surgical settings. Recent additions include EPIEFFECT, a lyophilized placental-based allograft introduced in September 2023 for acute and chronic wounds, and EPIXPRESS, a next-generation lyophilized placental allograft launched in October 2025 that features fenestrations for enhanced fluid movement. The company's products primarily address needs in advanced wound care, burn treatment, and surgical recovery. Additionally, MiMedx supplies allografts for ophthalmic and dental applications through various partnerships. The distribution model relies on a direct sales force, independent sales agents, and distributors, predominantly within the United States, including federal healthcare agencies. Recent strategic initiatives include a July 2025 collaboration with Vaporox, Inc. to co-promote wound care offerings, coupled with a strategic investment. Headquartered in Marietta, Georgia, MiMedx Group, Inc. reported record quarterly revenue of $114 million in Q3 2025 and full-year 2024 revenue of $349 million.
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript
MiMedx Group Q2 Earnings Call Highlights
MIMEDX Announces Second Quarter 2026 Operating & Financial Results
MIMEDX to Acquire Sanara MedTech
MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
Is the Options Market Predicting a Spike in MiMedx Group Stock?
MiMedx: The Hard Math Behind My Downgrade To Hold
MIMEDX Announces Launch of G4Derm® Plus
MIMEDX Announces Launch of G4Derm® Plus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
MiMedx Group, Inc. (MDXG) Q1 2026 Earnings Call Transcript
MiMedx (MDXG) Reports Q1 Loss, Tops Revenue Estimates
MIMEDX Announces First Quarter 2026 Operating & Financial Results